2 evolution "https:" "https:" "https:" "https:" "https:" "https:" "BioData" Fellowship positions at Université de Caen Normandie
-
via an interaction with the RIPK2 protein. (Fulda, Clin Cancer Res, 2015) The design of molecules that disrupt the XIAP/RIPK2 interaction could lead to the development of original and more selective
-
the development of new cancer therapies. Few UBE2N inhibitors have been described in the literature, and these are mainly covalent inhibitors, which, due to a lack of selectivity, expose patients
Enter an email to receive alerts for evolution "https:" "https:" "https:" "https:" "https:" "https:" "BioData" positions